Defining the functional role and potential as an immunotherapeutic target of ALCAM in neuroblastoma.

ABSTRACT: Despite intensive, multimodal therapy, only half of children diagnosed with high-risk neuroblastoma will survive five years, and survivors harbor significant short- and long-term treatment-related co-morbidities. Although monoclonal antibody therapy targeting GD2 has improved outcomes, GD2-directed immunotherapy remains one of the only FDA-approved immunotherapies for pediatric cancer, and therapy is toxic due to GD2 expression on pain fibers. Thus, there is a critical need to uncover new immunotherapy targets in neuroblastoma. ALCAM is a cell adhesion molecule that promotes tumor growth in a variety of cancers and is highly expressed in neuroblastoma. We generated three inducible CRISPRi cell lines to deplete ALCAM and elucidate its role in neuroblastoma. Depletion of ALCAM reduced cell g

SUBMITTER: Lindsay J 

PROVIDER: S-EPMC12729689 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature